Amended Statement of Beneficial Ownership (sc 13d/a)
April 20 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
CoLucid
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
19716T 101
(CUSIP
Number)
Peter Haahr
Novo A/S
Tuborg Havnevej
19
Hellerup, Denmark
DK-2900
+45 3527 6592
Copy to:
B. Shayne Kennedy, Esq.
Latham & Watkins LLP
650 Town Center Drive, 20
th
Floor
Costa Mesa, CA 92626
Telephone: (714)
540-1235
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 1, 2017
(Date
of Event which Requires Filing of this Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule
13d-1(e),
13d-1(f)
or
13d-1(g),
check the following box. ☐
Note:
Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule
13d-7(b)
for other parties to whom copies are to be sent.
*
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (the Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
Novo A/S
|
2.
|
|
Check the Appropriate Box if a
Member of Group (See Instructions):
(a)
☐
(b)
☒
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
WC
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to
Items
2(d)
or
2(e):
☐
|
6.
|
|
Citizenship or Place of
Organization:
Denmark
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
0
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
0
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
0
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
0.0%
|
14.
|
|
Type of Reporting Person:
CO
|
2
This amendment (
Amendment No.
2
) amends the Schedule 13D originally filed
with the Securities and Exchange Commission (the
Commission
) on May 13, 2015, as subsequently amended by Amendment No. 1 filed with the Commission on September 14, 2016 (the
Schedule
), to report
that as a result of the completion of the acquisition of the Issuer by Eli Lilly and associated Tender Offer (described below), the Reporting Person no longer has beneficial ownership of any of the Issuers shares. All capitalized terms
contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.
Item 5.
|
Interest in Securities of the Issuer
|
Items 5(a), (c) and (e) of the Schedule are amended and replaced
in their entirety as of March 1, 2017, as follows:
(a) As a result of the completion of the Tender Offer and
acquisition of the Issuer by Eli Lilly and Company (
Lilly
), and its wholly-owned subsidiary, ProCar Acquisition Corporation (
Purchaser
), the Reporting Person no longer has beneficial ownership of any of the
Issuers shares.
(c) Effective as of March 1, 2017, the Purchaser purchased all of the outstanding shares of
Issuers common stock, par value $0.001 per share (the
Shares
), including all of the 3,156,563 shares held by the Reporting Person, at a purchase price of $46.50 per Share, net to the seller in cash, without interest thereon,
upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 31, 2017, disclosed in the Tender Offer Statement on Schedule TO, filed by the Purchaser and Lilly with the Commission on January 31, 2017 (the
Tender Offer
).
(e) The Reporting Person ceased to be a beneficial owner of 5% or more of the
Issuers common stock on March 1, 2017.
3
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
|
|
|
|
Dated: April 19, 2017
|
|
|
|
Novo A/S
|
|
|
|
|
|
|
|
/s/ Peter Haahr
|
|
|
|
|
By:
|
|
Peter Haahr
|
|
|
|
|
Its:
|
|
Chief Financial Officer
|
Signature Page to Schedule 13D
Reporting Person: Novo A/S Issuer: CoLucid Pharmaceuticals, Inc.
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Mar 2024 to Apr 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Apr 2023 to Apr 2024